{"groups":[{"description":"Participants received bortezomib (Velcade) 1.3 mg/m\\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"FG000","title":"Bortezomib and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"FG001","title":"Bortezomib, Thalidomide, and Dexamethasone"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).","id":"FG002","title":"Bortezomib, Melphalan and Prednisone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"67"},{"groupId":"FG002","numSubjects":"65"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"8"}],"type":"Lack ofEfficacy / Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"13"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"11"}],"type":"Patient declined further treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"13"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"4"}],"type":"Did not Receive Study Treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"168"},{"groupId":"FG001","numSubjects":"167"},{"groupId":"FG002","numSubjects":"167"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"165"},{"groupId":"FG001","numSubjects":"158"},{"groupId":"FG002","numSubjects":"163"}],"type":"Treated (Safety Population)"},{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"69"}],"type":"Completed 8 Treatment Cycles"},{"achievements":[{"comment":"Completed is defined as having completed 13 treatment cycles.","groupId":"FG000","numSubjects":"50"},{"comment":"Completed is defined as having completed 13 treatment cycles.","groupId":"FG001","numSubjects":"42"},{"comment":"Completed is defined as having completed 13 treatment cycles.","groupId":"FG002","numSubjects":"53"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"114"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with previously untreated multiple myeloma were randomized in a 1:1:1 ratio to one of three treatment groups: VD: Velcade (bortezomib) and dexamethasone; VTD: Velcade, thalidomide, and dexamethasone; VMP: Velcade, melphalan, and prednisone.","recruitmentDetails":"Participants took part in the study at 158 investigative sites in the United States from 26 June 2007 to 28 March 2013"}